Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | PLA2G7 | Q13093 | 16/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9900913 | 0.94 | PLA2G7 (0.41) | GPR84PLA2G7BRAFKDRSCN9A | |
| SCHEMBL9923488 | 0.91 | PLA2G7 (0.35) | GPR84PLA2G7KDRSCN9A | |
| SCHEMBL9923513 | 0.90 | GPR84 (0.44) | GPR84PLA2G7BRAFKDR | |
| SCHEMBL9923530 | 0.89 | PLA2G7 (0.50) | GPR84PLA2G7BRAFKDR | |
| SCHEMBL9923491 | 0.89 | HTR2A (0.37) | GPR84PLA2G7BRAFKDR | |
| SCHEMBL15277238 | 0.88 | PLA2G7 (0.44) | GPR84PLA2G7BRAFKDR | |
| SCHEMBL9904748 | 0.84 | PLA2G7 (0.42) | GPR84PLA2G7BRAFKDR | |
| SCHEMBL9904843 | 0.84 | GPR84 (0.43) | GPR84PLA2G7 | |
| SCHEMBL15277241 | 0.83 | PLA2G7 (0.39) | GPR84PLA2G7KDRSCN9ASCN5A | |
| SCHEMBL9905023 | 0.83 | POLB (0.41) | GPR84PLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859573-B2 | Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| US-8859573-B2 | Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| US-20130252986-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252986-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| WO-2012075917-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252986-A1 | COMPOUNDS | LIPG, ENPP2, PLA2G1B | GPR84 773/4885PLA2G7 6/4885BRAF 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.